JP2019516707A5 - - Google Patents

Download PDF

Info

Publication number
JP2019516707A5
JP2019516707A5 JP2018560460A JP2018560460A JP2019516707A5 JP 2019516707 A5 JP2019516707 A5 JP 2019516707A5 JP 2018560460 A JP2018560460 A JP 2018560460A JP 2018560460 A JP2018560460 A JP 2018560460A JP 2019516707 A5 JP2019516707 A5 JP 2019516707A5
Authority
JP
Japan
Prior art keywords
fibromyalgia
general formula
group
alkyl
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018560460A
Other languages
English (en)
Japanese (ja)
Other versions
JP7071287B2 (ja
JP2019516707A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/KR2017/005173 external-priority patent/WO2017200318A1/ko
Publication of JP2019516707A publication Critical patent/JP2019516707A/ja
Publication of JP2019516707A5 publication Critical patent/JP2019516707A5/ja
Application granted granted Critical
Publication of JP7071287B2 publication Critical patent/JP7071287B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018560460A 2016-05-19 2017-05-18 繊維筋痛又は繊維筋痛の関連する機能的症候群を予防又は治療するためのカルバメート化合物の使用 Active JP7071287B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20160061392 2016-05-19
KR10-2016-0061392 2016-05-19
PCT/KR2017/005173 WO2017200318A1 (ko) 2016-05-19 2017-05-18 섬유근육통 또는 섬유근육통의 연관된 기능적 증후군을 예방 또는 치료하기 위한 카바메이트 화합물의 용도

Publications (3)

Publication Number Publication Date
JP2019516707A JP2019516707A (ja) 2019-06-20
JP2019516707A5 true JP2019516707A5 (enExample) 2020-06-25
JP7071287B2 JP7071287B2 (ja) 2022-05-18

Family

ID=60325216

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018560460A Active JP7071287B2 (ja) 2016-05-19 2017-05-18 繊維筋痛又は繊維筋痛の関連する機能的症候群を予防又は治療するためのカルバメート化合物の使用

Country Status (13)

Country Link
US (1) US10849882B2 (enExample)
EP (1) EP3459543B1 (enExample)
JP (1) JP7071287B2 (enExample)
KR (1) KR102489052B1 (enExample)
CN (1) CN109475529B (enExample)
AU (1) AU2017265839B2 (enExample)
BR (1) BR112018073553A2 (enExample)
DK (1) DK3459543T3 (enExample)
ES (1) ES2935596T3 (enExample)
MX (1) MX394245B (enExample)
PL (1) PL3459543T3 (enExample)
RU (1) RU2753525C2 (enExample)
WO (1) WO2017200318A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102635941B1 (ko) * 2016-12-14 2024-02-13 에스케이바이오팜 주식회사 진전 또는 진전 증후군의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도
EP3711757B1 (en) * 2017-11-14 2025-05-07 SK Biopharmaceuticals Co., Ltd. Use of a carbamate compound to prevent, alleviate or treat visceralgia or pain arising from visceral disease
ES2973111T3 (es) * 2017-11-14 2024-06-18 Sk Biopharmaceuticals Co Ltd Uso de un compuesto de carbamato para prevenir o tratar enfermedades asociadas con el aumento de la corriente tardía de sodio
CN111432812A (zh) 2017-11-14 2020-07-17 爱思开生物制药株式会社 用于预防、减轻或治疗失神发作或显示失神发作的癫痫的氨基甲酸酯化合物的用途
KR20210062029A (ko) 2018-10-19 2021-05-28 에스케이바이오팜 주식회사 카바메이트 화합물의 당뇨병성 말초 신경병증 또는 화학요법 유발 말초 신경병증의 예방, 완화 또는 치료를 위한 용도
AU2020389425B2 (en) * 2019-11-22 2026-03-05 Sk Biopharmaceuticals Co., Ltd. Oral pharmaceutical composition comprising carbamate compound and preparation method therefor
IT202300007314A1 (it) 2023-04-14 2024-10-14 Soal Pharma Srl Integratore alimentare per il trattamento della fibromialgia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3415840A (en) * 1965-10-22 1968-12-10 American Home Prod Pyrazole-1-ethanol derivatives
RU2299729C2 (ru) * 2001-07-16 2007-05-27 Орто-Макнейл Фармасьютикал, Инк. Карбаматные соединения для применения для предотвращения или лечения невропатической боли и боли, связанной с кластерной и мигреневой головной болью
US7598279B2 (en) * 2005-04-22 2009-10-06 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
AU2009348523B2 (en) * 2009-06-22 2015-02-26 Sk Biopharmaceuticals Co., Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester
US8404461B2 (en) 2009-10-15 2013-03-26 SK Biopharmaceutical Co. Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester
EP2496227B1 (en) * 2009-11-06 2019-05-22 SK Biopharmaceuticals Co., Ltd. Methods for treating fibromyalgia syndrome

Similar Documents

Publication Publication Date Title
RU2494095C2 (ru) Модифицированные миметики лизина
JP2016512531A5 (enExample)
JP2015532295A5 (enExample)
JP2020519661A5 (enExample)
JP2018524298A5 (enExample)
RU2019141734A (ru) Терапевтические соединения и композиции и способы их применения
RU2015143610A (ru) Лечение катаплексии
JP2014511892A5 (enExample)
RU2018144785A (ru) Применение соединения карбаминовой кислоты для профилактики или лечения фибромиалгии или функционального синдрома, ассоциированного с фибромиалгией
JP2016509047A5 (enExample)
JP2012530779A5 (enExample)
RU2017112048A (ru) Синергистические комбинации ауристана
JP2019516739A5 (enExample)
RU2009116455A (ru) Применение индуцирующих гипотермию лекарственных средств для лечения ишемии
JP2013509441A5 (enExample)
JP2018523689A5 (enExample)
CN102985085A (zh) 治疗双相型障碍的方法
JP2019516726A5 (enExample)
BRPI0618522A2 (pt) diaril uréia para o tratamento de hipertensão pulmonar
FI3506900T3 (fi) Ampreloksetiini käytettäväksi neurogeenisen ortostaattisen hypotension
JP2019516722A5 (enExample)
RU2015113959A (ru) Индолины
JP2014530204A5 (enExample)
WO2018217139A4 (ru) Новые ингибиторы глутаминилциклаз и их применение для лечения различных заболеваний
RU2016103098A (ru) Способ предотвращения и/или лечения хронической травматической энцефалопатии - ii